The study, published August 5, 2026, in Nature, integrates the 3D models into DepMap’s existing collection of more than 1,000 2D cancer models. Researchers found that the two model systems often captured different genetic dependencies, meaning that neither could provide a complete picture of cancer biology on its own. The 3D models also represented cancer subtypes that are difficult or impossible to maintain as conventional cell lines, including certain brain and gastrointestinal tumors. The findings suggest that the next generation of cancer research may depend on using multiple model formats rather than selecting a single “best” system.

Cancer dependencies are genes or molecular pathways that tumor cells require for growth, proliferation, or survival. In principle, disabling such a gene can selectively damage cancer cells while leaving healthy cells less affected. DepMap scientists systematically measure these dependencies by perturbing genes, often with CRISPR-based methods, and then observing whether cancer cells continue to grow. When these results are combined with information about mutations, gene expression, and cellular state, researchers can identify relationships between a tumor’s molecular features and its potential drug vulnerabilities.

Traditional cancer cell lines have been indispensable for this work because they are relatively easy to grow, manipulate, and screen at large scale. However, they are usually adapted to flat plastic surfaces and nutrient-rich laboratory media. During that adaptation, some features of the original tumor can disappear. Organoids and spheroids offer a different environment: cells grow in three dimensions, often within a gel matrix or as suspended clusters, allowing them to establish cell-cell contacts and structural states that more closely resemble those found in patient tumors. Brain tumor models may grow as neurospheres, while many gastrointestinal and pancreatic models are maintained as patient-derived organoids.

The Broad-led team found that 3D models retained mutations and cellular programs observed in human tumors but absent from the available 2D lines. These differences were linked to new genetic dependencies that could not be detected through traditional screening alone. The result is a more diverse dependency landscape, potentially expanding the number of drug targets available for cancers that have been poorly represented in standard laboratory systems. The researchers describe the expanded collection as a step toward a more complete map of the biological requirements that drive different forms of cancer.

One particularly striking example involved glioblastoma, an aggressive and frequently lethal brain cancer. Three-dimensional glioblastoma models lacking the tumor-suppressor gene CDKN2A were substantially more sensitive to suppression of CDK6 than models retaining an intact copy of the gene. CDKN2A normally helps restrain cell-cycle progression, while CDK6 promotes the transition toward DNA replication and cell division. The result indicates that CDKN2A loss may serve as a biomarker for identifying glioblastoma patients who could be more likely to respond to existing CDK6-targeting drugs, although the finding will require validation in additional models and clinical studies.

The researchers also uncovered a vulnerability in pancreatic and other gastrointestinal organoids. Some of these models maintained a gene-expression program previously associated with a clinically important pancreatic cancer subtype. That program was largely lost in conventional cell lines, making it difficult to study using standard approaches. Organoids carrying the transcriptional state depended on several genes involved in WNT signaling, a pathway that regulates cell identity, tissue organization, and stem-cell behavior. The result points to a possible therapeutic opportunity that is specific to a cancer state preserved in 3D culture and may help explain why certain tumors behave differently in patients than in conventional laboratory experiments.

The study further showed that experimental conditions can shape dependency measurements in distinct ways. Genes involved in cell adhesion and cytoskeletal organization were particularly sensitive to whether cells grew in two or three dimensions. By contrast, genes involved in lipid metabolism were influenced more strongly by the composition of the culture medium, regardless of the physical format. Changing either the growth geometry or the nutrients available to cells altered the genes on which they depended. These observations provide a technical warning for cancer researchers: a dependency observed in one culture system may reflect not only tumor genetics but also the artificial conditions used to maintain the cells.

The expanded DepMap also revealed why 2D models remain valuable. Some breast cancer cell lines contained tumor markers that were not found in any of the 3D models examined, showing that organoids do not automatically reproduce every clinically relevant feature. Instead, the two systems offer complementary views of cancer biology. By combining their data, researchers can compare dependencies across genetic backgrounds, tissue architectures, and cellular states, improving the chances of distinguishing broadly useful drug targets from vulnerabilities that emerge only in particular experimental environments. The new resource is now available through the DepMap portal, where scientists can use it to investigate cancer mechanisms, prioritize therapeutic targets, and choose model systems more strategically.

Subject of Research: Cells

Article Title: A dependency map enhanced with next-generation 3D cancer models

News Publication Date: August 5, 2026

Web References: Cancer Dependency Map portal; Nature article

References: Neiswender JV, Maffa S, Brenan L, et al. “A dependency map enhanced with next-generation 3D cancer models.” Nature. August 5, 2026. DOI: 10.1038/s41586-026-10843-7.

Keywords: Cancer Dependency Map, DepMap, organoids, spheroids, 3D cancer models, cancer dependencies, glioblastoma, CDKN2A, CDK6, WNT signaling, pancreatic cancer, gastrointestinal cancer, precision medicine, drug targets, Broad Institute

The technology, bolstered by a $1.7 million grant from the National Institutes of Health, represents a leap forward in exosome analysis by enabling the examination of individual exosomes with unprecedented precision. Traditional analytical methods have struggled to achieve adequate sensitivity and specificity, often requiring large sample volumes and relying heavily on DNA amplification and sequencing techniques, which can obscure the nuanced heterogeneity among exosome populations. In contrast, Shih’s novel approach aims to surmount these challenges by directly measuring the structural and molecular attributes of single exosomes, thereby facilitating the identification of specific exosome subpopulations that may serve as viable drug targets.

Central to this breakthrough is the Integrated Nanophotonic Imaging and Spectroscopy Technology (INSPECT), a cutting-edge platform that leverages advances in nanoplasmonics to probe exosomes at a scale and depth previously unattainable. Nanoplasmonics, which exploits the interaction of light with metallic nanostructures to amplify electromagnetic fields, enables the detection of minute molecular binding events and enhances fluorescence signals. INSPECT uniquely combines three complementary nanoplasmonic mechanisms: surface binding detection, fluorescence signal enhancement, and chemical composition analysis, providing a multidimensional characterization of individual extracellular vesicles.

The biological significance of exosomes extends across numerous fields, including oncology, neurology, regenerative medicine, and dermatology. These vesicles mediate cell-to-cell communication by transporting proteins, lipids, and nucleic acids, influencing pathological processes such as tumor progression, neurodegeneration, and tissue repair. Harnessing exosomes for liquid biopsy applications—non-invasive sampling of biomarkers from bodily fluids—and drug delivery systems holds transformational potential for precision medicine. Nonetheless, the heterogeneity and complexity of exosomes present formidable obstacles to their clinical translation.

Current techniques suffer from multiple pitfalls: they often require extensive sample preparation steps like purification, isolation, and labeling, which can introduce artifacts and impede high-throughput analysis. Isolation procedures can be time-consuming and may result in the loss of critical subpopulations of vesicles. Furthermore, existing tools lack the resolution to perform multi-parametric profiling at the single-exosome level, meaning that subtle but biologically significant variations remain undetected. INSPECT’s capacity to integrate structural imaging with spectral analysis addresses these shortcomings by enabling simultaneous assessments of size, morphology, molecular composition, and binding interactions on a per-exosome basis.

Shih’s prior research laid the foundation for this innovation by demonstrating the efficacy of three nanoplasmonic enhancing modalities for biosensing. First, plasmonic resonance sensors detect molecular binding events via changes in the refractive index near metallic surfaces, providing sensitive label-free detection. Second, plasmon-enhanced fluorescence amplifies signal intensity, improving detection limits without increasing background noise. Third, surface-enhanced Raman scattering (SERS) offers detailed molecular “fingerprinting” by amplifying vibrational spectra, revealing chemical compositions with high specificity. The integration of these modalities within INSPECT creates a synergistic platform capable of extracting rich, multidimensional data from single exosomes.

The profound implications of this technology extend beyond fundamental science into translational and clinical realms. By enabling multiplexed, high-throughput analysis of exosome populations, INSPECT has the potential to identify novel biomarkers indicative of disease states, monitor therapeutic responses, and facilitate the development of exosome-based drug delivery vehicles. Moreover, this approach could accelerate research into the roles of exosomes in neurological disorders such as Alzheimer’s disease, where early and accurate detection of pathological changes is paramount.

Despite the promise, challenges remain in scaling the technology for widespread adoption. The sensitivity and specificity of INSPECT must be rigorously validated across diverse biological samples and conditions. Collaborations with biologists, clinicians, and other engineers are crucial to tailor the platform for various applications, optimize sample processing protocols, and ensure compatibility with existing diagnostic workflows. Shih emphasizes the collaborative nature of this endeavor, inviting researchers interested in extracellular vesicle biology to partner in expanding the capabilities and utility of INSPECT.

In sum, the advent of Integrated Nanophotonic Imaging and Spectroscopy Technology marks a significant milestone in the study and application of exosomes. By illuminating these diminutive yet biologically potent vesicles with unprecedented clarity, this innovation opens vistas for novel diagnostic and therapeutic strategies that could transform patient care across oncology, neurology, and beyond. As the scientific community embraces and refines such technologies, the once opaque world of exosomes will become increasingly transparent, revealing new molecular signatures and intervention points that hold the key to combating some of the most challenging diseases of our time.

Subject of Research: Exosomes; Integrated nanophotonic imaging and spectroscopy technology for single exosome analysis; biomedical engineering.

Article Title: Illuminating the Invisible: Nanophotonic Advances in Single Exosome Analysis Unveil New Paths for Disease Diagnosis and Treatment.

News Publication Date: Not specified.

Web References: University of Houston (https://uh.edu), National Institutes of Health (https://nih.gov).

Image Credits: University of Houston.

Keywords: exosomes, nanoplasmonics, integrated nanophotonic imaging, spectroscopy technology, single exosome analysis, biomedical engineering, disease diagnostics, drug delivery, extracellular vesicles, liquid biopsy, Alzheimer’s disease, cancer biology, nanomedicine, biomedical technology.